• Ucore’s RapidSX(TM) Demonstration Plant will be located within the company’s 5000 square foot Commercialization and Demonstration Facility in Kingston, Ontario
• A Strategic Metals Complex is being planned in Louisiana with an initial capacity of 2,000 tonnes per annum and increasing to production of 5,000 tonnes
• Cerium, neodymium, lanthanum, praseodymium, yttrium, and dysprosium are expected to remain the most sought-after REEs, with high demands in magnet manufacturing and the automobile industry
• The global rare earth element market was valued at $2.8 billion in 2018 and is expected to grow at a CAGR of 10.4% through 2025

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company focused on Rare Earth Element (“REE”) resource development and precious metal commercialization, recently provided an update on the commissioning process for its RapidSX(TM) Demonstration Plant for the separation of heavy and light REEs. The demonstration plant is located within Ucore’s 5000 square foot RapidSX(TM) Commercialization and Demonstration Facility in Kingston, Ontario, and is run by its research development partner, Kingston Process Metallurgy Inc. (https://ibn.fm/qkkf8). Ucore’s vision includes becoming a leading advanced technology company that provides the best-in-class metal separation products and services to the mining and mineral extraction industry. The company also plans to aid in developing the North American REE supply chain controlled by the U.S. and its allies through strategic partnerships. Innovation Metals Corp., which was acquired by Ucore in 2020, developed the RapidSX(TM) technology – with early-stage assistance from the United States Department of Defense. This has resulted in the production of commercial-grade, separated REE at the pilot scale. Utilizing chemistry similar to traditional solvent-extraction (“SX”) technology, RapidSX(TM) is not “new” technology but rather a significant improvement on well-established, well-understood, and proven conventional separation technology preferred by leading REE producers. The global REE market was valued at $2.8 billion in 2018 and is expected to grow at a CAGR of 10.4% through 2025, with cerium, neodymium, lanthanum, praseodymium, yttrium, and dysprosium likely to remain the most commonly sought-after REEs. These REEs are expected to drive the market’s growth due to the increased demand for use in products in magnet manufacturing and catalysts for the automotive industry (https://ibn.fm/43P58). With the commissioning of Ucore’s demonstration plant, the company plans for the output of products that are high-purity NdPr, praseodymium, neodymium, terbium, and dysprosium REEs, to be incorporated into the early stages of original equipment manufacturers’ OEM qualification trials. The company is also working closely with partners to develop the full-scale engineering for the company’s first Strategic Metals Complex, with construction commencing in Louisiana this year. It is scheduled to have an initial capacity of 2,000 tonnes per annum of total rare earth oxides, increasing to 5,000 tonnes in 2026. “We are extremely pleased with the work at the CDF in concert with our partners, KPM, Mech-Chem, and a host of other supporting contractors and vendors. As we work toward near-term commercial deployment of the RapidSX™ rare earth element separation technology in North America,” said Ucore’s VP and COO, Mike Schrider, P.E. “Implementing the Demo Plant commissioning process is a huge milestone for the team, and this is scheduled to be followed by a series of heavy and light rare earth element process demonstrations separating tens of tonnes of mixed rare earth concentrates over thousands of hours of facility run-time.” For more information, visit the company’s website at www.Ucore.com. NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Market analysts predict monoclonal antibodies (“mAbs”) will be the fastest-growing revenue segment of the biologics medicinal market through the end of the decade
• BiondVax Pharmaceuticals is focused on developing and commercializing novel mAb “biobetter” NanoAbs to meet underserved medical needs addressing large market disorders
• The company’s recent work with an inhaled nanosized antibody for COVID has shown exceptionally promising results, virtually preventing illness and eliminating the SARS-COV-2 virus in a hamster population
• With COVID as first target, the company’s pipeline aims to provide effective medical responses to other disorders such asthma, psoriasis, psoriatic arthritis, and macular degeneration

Immunotherapeutic product innovator BiondVax Pharmaceuticals (NASDAQ: BVXV) is focused on developing, manufacturing, and commercializing innovative nanosized antibodies (NanoAbs) for the treatment of infectious diseases and autoimmune diseases, stepping up its pursuit of disrupting the monoclonal antibody (“mAb”) market amid forecasts that the global mAb market will grow at a compound annual rate (“CAGR”) of 11.30 percent through 2030. Grand View Research analysts reported recently that the global mAbs market size at the end of 2021 was valued at $185.50 billion and $210.06 billion by the end of 2022, with expectations it will reach $494.53 billion in revenues during the next eight years (https://ibn.fm/ki8n5). BiondVax’s recent work with innovative “biobetter” NanoAb therapies in diseases underserved by current mAb treatments has led to exceptionally promising results from a preclinical proof-of-concept study of its inhaled COVID-19 therapy, in which it virtually eliminated SARS-COV-2 virus in the lungs, and led to significantly shorter and milder illness, according to the company (https://ibn.fm/s598q). Additional results of the preclinical study also showed promising prophylactic results with the potential to provide proactive protection for at risk patients. “We continue to be thrilled with the results of this ongoing trial,” stated Amir Reichman, BiondVax’s CEO. (https://ibn.fm/q7ltP). “There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion. EVUSHELD is currently the only prophylactic COVID medication with FDA approval, under emergency use authorization. Our inhaled NanoAb is designed to be self-administered at the time of choosing to generate rapid protection from COVID illness. In contrast, EVUSHELD must be administered via two separate consecutive intramuscular (‘IM’) injections in a health care setting… we believe the additional ‘biobetter’ value provided by our NanoAb potentially positions it to capture significant market share both for treatment and prevention of COVID illness.” Its important to note that recent data show EVUSHELD is unlikely to be active against certain SARS-CoV-2 variants and as of January 26, 2023, EVUSHELD is no longer authorized by the FDA for use in the U.S. (https://ibn.fm/fCEc6). AstraZeneca reported that EVUSHELD had generated $1.451 billion in revenue from Q1 through Q3 2022 (https://ibn.fm/bBAGS). BiondVax aims to fill the growing void in COVID prophylactics and therapeutics. BiondVax’s pipeline of NanoAbs is expected to provide biologics that interact with previously validated therapeutic targets and have strong potential for significant advantages over currently approved human mAbs. “NanoAbs being generated at MPI demonstrate several unique attributes such as greater binding affinity, stability at high temperatures, and formulation advantages,” Reichman stated. “We believe that if NanoAbs with these attributes can be successfully developed they would provide an opportunity to capture a meaningful share of several large and growing markets while reducing upfront costs and risks commonly associated with new drug development (e.g., biological target validation) and accelerating initiation of clinical development.” There’s and old adage that ‘good things come in small packages’ and indications are that BiondVax’s NanoAbs may soon prove the adage true. For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Lexaria has developed the DehydraTECH drug delivery technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs
• DehydraTECH has been shown to increase intestinal bioabsorption of certain bioactive compounds by as much as 27 times, with its onset of action being as little as 1.5 minutes
• The technology is also expected to lower the overall drug costs because it delivers more active molecules to the blood plasma and brain, thus necessitating lower dosing, all while resulting in cost-effective manufacturing
• DehydraTECH is protected by 28 patents granted worldwide, with approximately 50 more pending

Speaking during a late 2022 interview (https://ibn.fm/cWQJX), Chris Bunka, the Chairman and CEO of Lexaria Bioscience (NASDAQ: LEXX), emphasized the varied applications of DehydraTECH(TM), and that, for example, the company intends to help people quit smoking by enabling them to satisfy their nicotine cravings in a way that will not kill them: pouches. This comes against a backdrop of worrying statistics, which show that over 480,000 people in the United States (https://ibn.fm/mE4f3) and over 8 million people globally (https://ibn.fm/lSxYa) die annually from cigarette smoking. Lexaria also sees an opportunity to help people with hypertension, which affects about 116 million people in the US (https://ibn.fm/cqKRT) and seizure disorders, which affect 3.4 million people in the US and 65 million globally (https://ibn.fm/v87fO). “We really do believe Lexaria is going to make the world a better place,” Bunka emphasized in closing. The company’s belief in a better tomorrow is anchored in its patented DehydraTECH technology, which enhances the performance of multiple categories of fat-soluble active molecules and drugs available in various formats, including oral ingestible, oral buccal/sublingual, and topical products. According to Lexaria, its technology “is best thought of as an additional layer that improves the effectiveness of existing or planned new products for companies that offer consumer supplements, prescription and non-prescription-based drugs, and nicotine products” (https://ibn.fm/RuNmo). When analyzed in terms of numbers, the improvements are impressive. Having conducted both in vitro and in vivo studies, Lexaria has established that DehydraTECH increases intestinal bioabsorption of certain bioactive compounds by as much as 27 times. Furthermore, given the technology increases the quantity of each active ingredient delivered to the blood plasma and brain, it reduces the need for high doses, ultimately contributing to lower overall drug costs as lower doses can still achieve the same or even better results. In addition, the technology works rapidly, with the DehydraTECH formulations’ effects becoming prominent in as little as 1.5 minutes post-administration. Other benefits include masked taste and smell of the active molecules, which has the intended effect of helping manufacturers create low-sugar products with fewer calories and avoid using artificial sweeteners. Manufacturers can also register other benefits, especially considering the process is very cost-effective, according to the company. “Micro quantities of fatty acids (Generally Recognized as Safe, or GRAS, ingredients) are incorporated into drugs, consumer packaged goods, and capsule products at a fraction of a penny per serving,” the company’s website reads. “DehydraTECH technology works with process equipment readily found in most commercial kitchen/production facilities, is easily utilized under GMP certification as needed, and is highly scalable.” The technology, which is protected by a robust suite of 28 patents granted worldwide (https://ibn.fm/fOmIF), has so far been used to enhance the capabilities of cannabidiol (“CBD”), nicotine, antivirals, and PDE5 inhibitors, to mention a few, with pharmacokinetic studies evaluating the resultant formulations showing positive results. The recently completed HYPER-H21-4 study, for instance, which evaluated DehydraTECH-CBD as a potential treatment against hypertension, showed that the formulation resulted in statistically significant lowering of 24-hour ambulatory blood pressure as well as sustained blood pressure reduction (https://ibn.fm/64eAI). HYPER-H21-3 showed attenuated pulmonary artery systolic pressure (https://ibn.fm/CY8CH), while HYPER-H21-2 evidenced up to a 23% reduction in overnight blood pressure and reduced arterial stiffness (https://ibn.fm/k3usL). Lexaria is currently preparing the paperwork needed to file an Investigational New Drug (“IND”) application with the Food and Drug Administration (“FDA”) as a precursor to commencing registered clinical trials. Separately, in an animal study, Lexaria showed that DehydraTECH-nicotine delivered through the mucous membrane in the mouth resulted in a 10-20x reduction in time to deliver peak levels of nicotine to the bloodstream and 2-3x higher levels of nicotine in the blood (https://ibn.fm/YIJ9V). In yet another animal study comparing DehydraTECH-CBD to Epidiolex(R), the first and only FDA-approved CBD medication for the treatment of seizures, Lexaria observed that its formulation appeared to demonstrate effectiveness at lower doses and more rapidly than Epidiolex (https://ibn.fm/Zhg3G). By targeting conditions and spaces that affect millions of lives, Lexaria is indeed working to make the world a better place, alleviating the suffering of scores of people. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• 30-year fixed-rate mortgages with conforming loan balances of $726,200 or less, saw rates decrease from 6.42% to 6.23% for the week ending January 18, 2023, resulting in a 28% increase in mortgage application volume, and a 34% increase in refinance demand
• It is projected that by the end of 2023, mortgage rates in the country will drop by 5.25%, coming from 2022, which saw home financing costs nearly double
• These rate drops present an opportunity for REZYFi to grow its customer reach, market share, and revenue but also offer an avenue for the growth of the housing finance sector

REZYFi, a growth mortgage origination and specialized financing company based in the United States is set to see a growth in the demand for its services in response to the changing financing market that has seen a drop in interest rates in the past few weeks. January 18, 2023, saw mortgage rates hit the lowest level since September 2022, and the market reacting with an increased demand for mortgages (https://ibn.fm/MPApD). Rates decreased from 6.42% to 6.23% for the average 30-year fixed-rate mortgages with conforming loan balances of $726,200 or less. In turn, mortgage application volume grew by nearly 28%, while refinance demand increased by 34% on the week ending January 21 compared to the previous week. In addition, it is projected that as more homes are listed on the market, the rates could go even lower, resulting in a further increase in mortgage demand. “As we enter the beginning of the spring season, lower mortgage rates and more homes on the market will help affordability for first-time homebuyers,” noted Mike Fratantoni, MBA’s senior vice president and chief economist. As a company that offers origination, structures, and investments in first mortgage loans and alternative structured financings secured by commercial real estate properties, the recent developments are much welcome. Of note is the anticipated sustained increase in the additional demand for mortgages, particularly given that 2022 saw home financing costs nearly double. Furthermore, it is projected that by the end of the 2023 calendar year, mortgage rates in the United States will drop to 5.25%, according to Bankrate (https://ibn.fm/mLGFE). While it will not be anything like pre-pandemic lows, it would still be significant in making real estate ownership more accessible and affordable, which is something REZYFi is looking to achieve. The growing acceptance of cannabis-derived products and the support the industry has received so far are an opportunity for REZYFi and an avenue for the growth of the finance sector. The conversation surrounding the products and the companies that deal with cannabis has helped advance policy, creating an opportunity for companies such as REZYFi, and presenting customers with options. The dropping mortgage rates reflect an industry that is responding to the times. With this comes an even more significant opportunity for REZYFi to increase its customer reach, market share, and revenue. Already, the company is positioning itself to cater to its target market and the challenges associated with lending to companies and individuals within the cannabis space. With the anticipated launch of its high-margin cannabis division and the development of proprietary technology, REZYFi is stamping its position as a market leader. But, more importantly, it is reaping the rewards of an industry that is slowly improving in performance and proving more accommodating, albeit slowly, to stakeholders in the cannabis space. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Brian recently joined Bell2Bell’s Stuart Smith in a podcast episode in which he discussed his and the company’s background, motivation to found SideChannel, existing market opportunities, 2022 milestones, and plans for 2023 and beyond
• SideChannel, a provider of cybersecurity services and products, helps mid-market companies simplify cybersecurity
• The company was founded in 2019 after CEO Brian Haugli observed a business opportunity in the largely underserved market
• Over the years since, the company has grown, posting $4.8 million in revenue in 2022, up from $2.8 million in 2021

During his stints at the US Department of Defense (“DoD”) and Pentagon, and later upon entry into corporate America, Brian Haugli made an observation: US Government agencies and, crucially, large American corporations, relied on mid-market companies, innovative startups, and smaller organizations for important products and services. This reliance often meant that the security posture of the large companies and government agencies ultimately depended on the security posture of the smaller partner firms that had access to critical data. Unfortunately, cybersecurity products at that time were predominantly targeted at major enterprises, meaning most small and mid-sized businesses (“SMBs”) could not afford them. This left an underserved market and a massive business opportunity that SideChannel (OTCQB: SDCH) intended to capitalize on when it launched in 2019. At the helm of the then-new startup was Brian, who now serves as the company’s CEO.  To ensure success, he surrounded himself with an executive team comprising people who also saw the existing gap, liked the business model he put together, and wanted to join him on the mission to building a program dedicated toward mid-market and small businesses, a market that is still underserved to date. And the journey has been, as he described in a recent interview with Bell2Bell’s Stuart Smith, “amazing.” As part of the interview, Brian provided more information about the company’s evolution from its inception, touching on his and the company’s background, motivation to found SideChannel, existing market opportunities, 2022 milestones, and plans for 2023 and beyond (https://ibn.fm/nOytd). “Our job is to make cybersecurity simple and accessible. We are a cybersecurity firm with products and services, and we bring a wealth of experience from our collective backgrounds,” explained Brian. “Our focus is to bring real cyber security expertise, solid products and services, tech-enabled services into the types of companies that usually can’t actually afford full-time resources [and] the right types of resources. So, we’re predominantly focusing on the middle market and startups, and it’s been an underserved market.” SideChannel, through its collective of expert virtual Chief Information Security Officers (“vCISOs”), builds and leads cybersecurity programs exclusively for SMBs. The vCISOs are attached to client companies where they own the cybersecurity budget, choose the right technological products for their needs, participate in hiring engineers and architects to deliver and execute within the cybersecurity programs, build the right processes, report to leadership about the goings on, and manage the programs over the long term. This long-term approach, according to Brian, sets SideChannel apart from the competition, which mostly only focuses on using technology to identify attacks or merely undertaking short-term assessments. Coupled with the increased uptake of cybersecurity solutions due to the growing need by companies to protect themselves from cyberattacks and comply with cybersecurity regulations, this approach has contributed to tremendous growth for the company. In 2021, for example, SideChannel reported $2.8 million in revenue, a figure that grew to $4.8 million in 2022. And as a continued testament to the growth, the company is hiring more CISOs and people on its sales team as well as developing new services that best suit its client’s needs. “In February, we will post our [Form] 10Q, and you will see this rise and growth,” Brian continued. The fiscal year 2022 saw the company not only post revenue growth but also announce the development of Enclave, a proprietary software product designed to provide network segmentation. According to Brian, this product creates an inventory of the assets within a networked environment, documenting everything that needs protection. It then isolates the various components that make up this environment, cordoning off attackers and helping reduce the damage an attacker can inflict on a system. “We [created and launched Enclave] because we had a client base that told us this is what they needed. We did it because we knew that [asset inventory and segmentation of networks are] top controls to be addressed inside of all cybersecurity standards that are out there and frameworks that companies follow,” explained Brian. “And then, the products that are available in the marketplace are predominantly built for just the enterprise, which means the midmarket cannot afford the solution that everyone is saying they should be going for, and we are seeing people need.” SideChannel expects to begin recognizing revenue from the Enclave product during the fiscal year 2023 (https://ibn.fm/vaH81). Still, the company also anticipates incorporating new features and capabilities into this product in addition to developing and launching other products to address systemic gaps that prevent mid-market clients from finding the right products. The company also intends to evolve and develop its M&A strategy, which will see it bring under its umbrella operations that were previously outsourced to partners. “So, areas that we traditionally went to partners for, we will either be able to build those capabilities ourselves or acquire those capabilities or other resources from those partners and bring those in,” said Brian. “We are becoming Cybersecurity-as-a-Service for companies, and for us to have all those capabilities [under one umbrella], it gives our clients a one-stop-shop to [access] all these functions.” And with companies increasingly recognizing the need for their vendors and B2B clients to safeguard their security posture, SideChannel is primed to articulate this need and manage that narrative to its customers’ customers. “It is a niche. It is an area that is growing, and to date, I cannot say I have seen anybody else doing what we are doing, which is [exciting]. But we see a lot of other folks out there trying to do something similar, and we are beating them on capabilities and value,” Brain continued. “So, it tells me that there is an expanding need for this – we are not the only game in town. But it also tells me that we are doing it the way clients are looking for, not just reselling the product or some service out there. We are really bringing a lot of value to our clients, which they recognize.” To listen to the full interview, please visit https://ibn.fm/xqvoJ For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• McEwen Copper’s Los Azules Project is a large porphyry copper-gold-silver deposit with considerable growth potential, with ultimate depth and lateral extents that remain to be determined
• McEwen Copper, subsidiary of McEwen Mining, is expected to be game-changing, possibly becoming the world’s next copper unicorn
• The copper mining market was valued at $75 billion in 2021 and is expected to reach $80 billion by 2029

McEwen Mining (NYSE: MUX) (TSX: MUX), an asset-rich diversified gold and silver producer in the Americas, with large exposure to copper through its 68-percent-owned subsidiary McEwen Copper, has reported rich copper values over attractive widths, resulting from infill drilling at its Los Azules project. Located in San Juan, Argentina, Los Azules is a large porphyry copper-gold-silver deposit expressing great potential, with ultimate depth and lateral extents yet to be fully determined. The report cites widespread mineralized magmatic-hydrothermal breccias with intercepts such as 237.2 meters (m) of 1.05% copper (Cu), including 108 m of 1.71% Cu in hole AZ22173. Northern exploration hole AZ22174 targeting a deep geophysical anomaly intersected multiple copper-mineralized horizons, including disseminated and veinlet-hosted primary copper mineralization and potassic alteration as deep as 1,100 m downhole, with assays pending. The report also showed the continuity of an Enriched mineral zone up to 300 m, true thickness (https://ibn.fm/9Qt3G). McEwen Copper resumed its drilling program in October 2022. It is designed to increase drill hole density and upgrade the copper resource classification to better understand the payback pit design. Also, the program will provide metallurgical, hydrological, and geotechnical data to facilitate mine design and to determine how much larger the deposit could be. “We entered 2023 with tremendous momentum, with nine drills operating, an active community engagement program, and a technical team advancing Los Azules towards feasibility,” said Michael Meding, Vice President and General Manager of McEwen Copper. “We are delivering a first-class technical evaluation on a copper deposit that will put Argentina at the forefront of critical metals production, supporting worldwide electrification and a greener future for generations to come.” The copper mining market was valued at $75 billion in 2021 and is forecast to grow $80 billion by 2029. The increase in development and construction initiatives in emerging and developing economies is expected to drive the global copper mining market. Most mined copper is currently used in infrastructure and new critical demand emerging for use in the electrification of transportation and the global energy transformation. (https://ibn.fm/qB7ZP). McEwen Copper is expected to be a game changer, potentially becoming the world’s next copper unicorn, and thus turbocharging McEwen Mining’s share value. McEwen Mining’s management team has extensive knowledge and expertise in the industry, owning and operating mines in some of the most prolific gold-producing regions in the Americas. In recent months, McEwen Mining has been successful lowering production costs and increasing production across its gold assets, driving some costs below industry averages. Gold, silver and copper prices are forecasted to enter major uptrends over the next couple of years. Beyond McEwen Copper, McEwen Mining also has important gold and silver projects: The Fox Complex, The Gold Bar Mine, San Jose Mine, and Project Fenix. For more information, visit the company’s website at www.McEwenMining.com. NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at http://ibn.fm/MUX

• Eloro Resources announced the successful completion of its primary share issuance in late January, 2023
• The placement, which comprised of over 3.4 million primary shares issued at a price of c$3.15, raised gross proceeds of approximately C$10.9mn
• The proceeds will be destined to Eloro’s ongoing Bolivian mining operations as well as general corporate purposes
• Eloro Resources is set to disclose its initial resource estimates for its flagship Iska Iska Project in coming months

Eloro Resources (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, announced that it had successfully concluded its previously announced, fully-underwritten primary share placement on January 27th, 2023. The offering, which consisted in Eloro issuing 3,466,540 primary shares at a price of C$3.15 per share, raised total gross proceeds of C$10,919,570; the figure also includes shares granted as part of the over-allotment option granted to underwriters. The offering was led by Cantor Fitzgerald Canada Corporation as lead underwriter and sole bookrunner, with Cormark Securities Inc., Haywood Securities Inc., National Bank Financial Inc., Scotia Capital Inc., and Stifel Nicolaus Canada Inc forming pact of the underwriting syndicate (https://ibn.fm/Z1K1u). In addition to the successful completion of the deal, Eloro Resources simultaneously revealed that two company directors had participated in the bookbuild process, subscribing for the equivalent of C$147,420 in new shares. The related party transaction will drive insider ownership of the company’s free float to well over 15%, further reinforcing the management’s strong ties to the firm’s underlying corporate performance (https://ibn.fm/P7IFs). Eloro Resources have further revealed that the net proceeds derived from the offering will be destined toward exploration and development purposes at the company’s ongoing mining projects in Bolivia as well as for general working capital and corporate purposes. Eloro Resources’ chief mining asset within Bolivia comprises of the Iska Iska project, a 484 square kilometre undeveloped mining tract within the Potosi region – located a mere 180 kilometers south of the prolific Cerro Rico deposit, long renown as richest silver deposit throughout history. Since commencing the inaugural drill program at the Iska Iska site in September 2020, Eloro Resources has drilled over 120 holes and 85,000 meters within the property, however it was their initial discoveries in late 2020 that convinced the company of the site’s relative potential. Between November 2020 and January 2021, the company found that its initial holes – most of which were between 250 and 300 meters in length, were delivering bulk tonnage of 150 silver grams equivalent per ton – a level of silver concentration which has been found to be economically viable for mining purposes in the past. More recently, Eloro Resources has sought to expand on its holdings within the Potosi region, acquiring the Mina Casiterita and Mina Hoyada properties, both of which adjoin the existing Iska Iska deposit towards the property’s western and south-western boundaries. The company has now set its sights towards completing and publishing their initial resource estimates for the Iska Iska project by March 2023, a process which is being carried out in collaboration with mining consultancy, Micon International. Research reports published by research brokerages Cantor Fitzgerald and Haywood Capital Markets have previously forecast Eloro Resources’ potential silver deposit estimates at ‘630 MMox AgEq’, a figure which may be further supplemented by tin production akin to a ‘40 ktpd operation, for annual product 106 Mlbs of SnEq’.  Following the company’s successful capital raising exercise and benefitting from exponential demand growth for both, silver and tin as a result of the ongoing global transition towards renewable energy sources, Eloro Resources look well placed to capitalize on any forthcoming resources discoveries in the coming months. For more information, visit the company’s website at www.EloroResources.com. NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

• MetAlert, a developer of personal protective medical equipment and supplies, owes much of its growth to acting on feedback from real-world caregivers who use its products for the monitoring and tracking of vulnerable patients
• This connection with caregivers has yielded advanced products such as the award-winning, multi-patented GPS SmartSole, Invisabelt, Take-Along Tracker, and Rover Tracker, among others
• Attention to consumers has also led to its line of hearing aids, such as its flagship Hear IQ 4 rechargeable, app-controlled hearing aid, and its RoomMate wall-mounted 3D sensors for looking after patients without intruding on their personal space

MetAlert (OTC: MLRT), a developer of personal protective medical equipment and supplies and a pioneer of wearable GPS, human, and asset tracking systems, pays constant and close consideration to feedback from real-world caregivers, and the needs of those who use its products. With over 20 years of experience and an extensive patent portfolio, the company is continually developing viable solutions to individuals afflicted with Alzheimer’s, dementia, and autism (“ADA”), making it one of the few companies that offer practical solutions specific to this group of individuals. MetAlert is driven by the need to engineer solutions to everyday challenges while maintaining a non-invasive approach to the carrier. This approach has yielded products such as the award-winning, multi-patented GPS SmartSole, the world’s first hidden wearable GPS tracking solution, as well as Invisabelt, Take-Along Tracker, and Rover Tracker, among others. In addition, MetAlert’s Monitoring Portal, accessible via web login, allows caregivers to track those possessing these devices, affording them better care (https://ibn.fm/KY87Z). General quality-of-life improvements are integral to MetAlert’s overall approach to business. This is evidenced by its line of hearing aids, ranging from its flagship Hear IQ 4 rechargeable, app-controlled hearing aid to its RoomMate wall-mounted 3D sensors for looking after patients without intruding on their personal space. Focusing on such a unique market has allowed the company to grow its market share and reach. It is expected to grow even further in the new year, especially given its recent strategic acquisition of TrakTec LLC. “It is really about increasing the quality of life, the longevity or people that are challenged,” noted Patrick Bertagna, MetAlert’s CEO (https://ibn.fm/dtMj4). According to PatSnap, in 2019, over 722 million wearable devices were in use globally, with the number expected to hit one billion by the end of 2023. This, coupled with the fact that non-communicable diseases claim over 41 million lives each year and about 17 million annually before they reach the age of 70, presents a growing need for robust, practical, and effective patient monitoring systems, a need which MetAlert is looking to satisfy (https://ibn.fm/e12Ad). In addition, the growing attention to lifestyle wellness factors creates a market for the company’s products. Its unique approach to their development and marketing sets it apart from its peers, allowing it to impact even more lives as time progresses. Having had an incredible start to the new year, MetAlert remains committed to growing its platform and range of products and services. It also remains committed to offering solutions with real-world caregivers and businesses in mind, providing resolutions to everyday challenges, and bringing quality-of-life improvements to persons living with ADA. For more information, visit the company’s website at www.MetAlert.com. NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products
• The company is developing nanosized antibodies (“NanoAbs”) addressing large market diseases underserved by current treatments, with its lead candidate targeting COVID-19
• The FDA recently revoked the sole authorization of a COVID prophylactic, Evusheld, citing the inability of the monoclonal antibody cocktail to neutralize emerging subvariants of the Omicron variant
• BiondVax’s lead NanoAb candidate shows superior advantages to monoclonal antibodies, with the data gathered strengthening the value proposition of the COVID-19 NanoAb as a safe, efficacious, and convenient therapeutic and prophylactic drug

The Food and Drug Administration (“FDA”) recently withdrew the authorization of AstraZeneca PLC (NASDAQ: AZN)’s Evusheld, a combination of two monoclonal antibodies (“mAbs”), which was being marketed as a pre-exposure prophylaxis to prevent COVID-19 infection among people with moderate to severe immune compromise (https://ibn.fm/zmmHn). The agency revoked the authorization citing the expectation that Evusheld may not neutralize the XBB.1.5 sub-variant of the Omicron variant. In fact, according to the FDA, sublineages not neutralized by the antibody therapy are presently causing at least 90% of infections. Evusheld’s cancellation is the latest in a series of withdrawals, with the FDA having previously revoked the authorization for emergency use of bebtelovimab, another monoclonal antibody therapy, because it was not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1 (https://ibn.fm/IhUqw). “Beyond Evusheld, the virus’s evolution has also left the country without any antibody therapies for patients once they are infected,” reads an article in Stat News (https://ibn.fm/Vm5sL). However, BiondVax Pharmaceuticals (NASDAQ: BVXV), a Jerusalem-based biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, is working on changing this grim reality. In fact, the company’s leading inhaled nanosized antibody (“NanoAb”) candidate, which is currently being prepared for clinical trials, has shown neutralization of all relevant Omicron subvariants. “Indeed, the emergence of new variants remains a concern, and NanoAb therapeutics have the potential to quickly and effectively address new variants,” wrote CEO Amir Reichman in his 2022 letter to shareholders (https://ibn.fm/uOpcQ). “Our collaborators at the Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”) have generated libraries each with ~300 million COVID-19 NanoAb candidates, as compared to mAb libraries that contain only thousands of options. Thus, as new variants emerge, we would expect to be in a position to rapidly develop a new neutralizing NanoAb.” With the cancellation of these monoclonal antibody therapies, originally authorized to help protect high-risk populations from the ever-evolving SARS-COV-2 virus, the value of BiondVax’s NanoAb-based COVID-19 therapeutic currently under development has never been clearer. Developed in collaboration with Germany-based MPI and UMG, the alpaca-derived NanoAbs have demonstrated unique characteristics such as greater formulation advantages, stability at high temperatures, and binding affinity than mAbs. Moreover, NanoAbs have shown strong potential for superior clinical outcomes, safety, and patient convenience at lower costs than mAbs, which have generated billions in annual commercial sales. In fact, BiondVax’s ongoing preclinical in vivo study is convincingly demonstrating the unique capabilities of its inhaled COVID-19 therapy. As reported by the company in November 2022, animal models treated with BiondVax’s inhaled NanoAbs experienced a milder and shorter illness (https://ibn.fm/FTm6x). The company also announced early January 2023 that the inhaled therapy virtually eliminated the SARS-CoV-2 virus from the animal models’ lungs (https://ibn.fm/2GKAy). In the most recent announcement, BiondVax reported its inhaled therapeutic virtually prevented illness when administered prophylactically. Obviously, this data strengthens the value proposition of the COVID-19 NanoAb as both a therapeutic and prophylactic drug. “COVID vaccine uptake is declining, effectiveness wanes over a short period of time, and vaccination campaigns demand vast health care system resources. We believe the additional ‘biobetter’ value provided by our NanoAb potentially positions it to capture significant market share both for treatment and prevention of COVID-19 illness,” commented Reichman in a January 23 news release reporting the prophylactic properties of the NanoAbs (https://ibn.fm/YpEYG). BiondVax aims to fill the existing void in COVID prophylactics and treatments, which, as sales figures indicate, is strong. AstraZeneca, for instance, reported that Evusheld had generated $1.451 billion in revenue from Q1 through Q3 2022 (https://ibn.fm/UPZ8M); and even with its limitations, Paxlovid, an antiviral medication developed by Pfizer Inc. (NYSE: PFE), generated $18.9 billion in sales in 2022 (https://ibn.fm/6sOdX). BiondVax’s NanoAbs may be the key to an effective, economical, and easy to use solution for COVID therapeutics and prophylactics. With human clinical trials scheduled for later this year it certainly makes sense to keep BVXV on the radar. For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Data443 Risk Mitigation recently revealed it had submitted and filed its 2022 Form 10-K with the SEC
• The filing will mark the company’s fourth full year of audited financial statements filed with the SEC
• In turn, this would exempt the company from meeting minimum share price requirements imposed by The Nasdaq Capital Market on companies created by way of a reverser merger and seeking to up list on to the index
• A potential uplisting would mark the latest achievement for Data443, with the company recently revealing a new contract win as well as a capital raising designed to fund its future growth endeavors

Data443 Risk Mitigation (OTC: ATDS), a data security and privacy software company, recently revealed that the company had filed and submitted its annual 10-K form for its fiscal year ended December 31, 2022 (https://ibn.fm/RMIVX). Following the filing of its Form 10K, Data 443 stated that it would no longer be subject to the Nasdaq Capital Market (Nasdaq)’ higher seasoning threshold for price compliance, an event which the company hopes will hasten its uplisting to the Nasdaq main board. The Nasdaq exchange currently applies heightened ‘seasoning’ rules to all companies which have completed reverse mergers and do not yet have four full years of audited financial statements on file with the Securities and Exchange Commission (“SEC”). As per Nasdaq listing rule 5110 (c), a company must satisfy a 30-of-60-day price requirement, wherein the listed company must show that it has achieved a closing bid price of at least $4.00 per share for 30 of 60 days prior to the filing of the company’s initial listing application with Nasdaq and prior to the actual listing of the company’s securities on Nasdaq. Nevertheless, and with the filing of its 2022 Form 10-K, Data443 will meet the hurdle of having four full years of audited financial statements with the SEC, thereby voiding the need to comply with the Nasdaq rule. “We are excited to file our 2022 Form 10-K and, as a seasoned issuer, no longer be subject to Nasdaq’s 30-of-60-day price requirement. We remain hopeful that completion of our planned public offering and price compliance at that time will enable the company to complete our up list to Nasdaq. I am also hopeful that doing so will further position the company as a prominent cybersecurity and data management company. Delivering on our business plan continues to be our top priority. As stated previously, our efforts to up list to Nasdaq are central to our continued funding, acquisition strategy, and organic growth efforts,” said CEO and founder, Jason Remillard. A potential uplisting to the Nasdaq market would have significant benefits attached to it, with the Nasdaq currently positioned as the most active stock trading venue in the U.S. by volume. Moreover, it would mark yet another accomplishment in Data443’s recent illustrious history. Data443 recently revealed that its flagship antivirus product, Data443(R) Antivirus Protection Manager^™ had received its VB100 certification. A coveted designation administered by the industry’s leading reporting agency, Virus Billeting, the VB100 certification affirms that Data443’s antivirus product satisfies a broad array of criteria, including detecting all known-in-the-wild viruses, generating no false positives, and having the ability to perform both, scheduled and on-demand scans. Separately, Data443 also revealed that it had recently been awarded a new $350,000 contract with a leading global investment bank, relating to the licensing of Data443’s data placement manager. Elsewhere, the company announced that it had successfully carried out a $750,000 capital raising towards the end of last year, with net proceeds set to be destined towards financing general corporate expenditures, the recruitment of additional workers as well as the potential uplisting of the company to the Nasdaq Capital Markets in 2023 (https://ibn.fm/Kmmzt). Data443 Risk Mitigation, Inc. (ATDS) Investor Relations Matthew Abenante ir@data443.com 919-858-6542 For more information, visit the company’s website at www.Data443.com. NOTE TO INVESTORS: The latest news and updates relating to ATDS are available in the company’s newsroom at https://ibn.fm/ATDS